A reverse 230 U/ 226 Th radionuclide generator for targeted alpha therapy applications

Thorium-226 (half-life 30.6 m) is a radionuclide of interest for use in targeted alpha therapy applications. Due to its short half-life, Th must be provided through a radionuclide generator system from its parent U (20.8 d). Furthermore, as the half-life of Th is very short, it should be provided in...

Full description

Saved in:
Bibliographic Details
Published in:Nuclear medicine and biology 2020-11, Vol.90-91, p.69
Main Authors: Mastren, Tara, Akin, Andrew, Copping, Roy, Brugh, Mark, Wilbur, D Scott, Birnbaum, Eva R, Nortier, Francois M, John, Kevin D, Fassbender, Michael E
Format: Article
Language:English
Subjects:
Alpha Particles - therapeutic use
Radiochemistry - instrumentation
Radiochemistry - methods
Radioisotopes - chemistry
Radionuclide Generators
Thorium - chemistry
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thorium-226 (half-life 30.6 m) is a radionuclide of interest for use in targeted alpha therapy applications. Due to its short half-life, Th must be provided through a radionuclide generator system from its parent U (20.8 d). Furthermore, as the half-life of Th is very short, it should be provided in a form that is directly amenable to use in biomedical applications. A reverse radionuclide generator system was developed employing a DGA extraction chromatography column. A U/ Th parent/daughter solution in equilibrium is added to a DGA column in >6 M HCl. The parent U is eluted first in 0.1 M HNO followed by elution of Th in 0.1 M citrate buffer pH 5. Thorium-226 was recovered from the radionuclide generator column with >96% yield. Greater than 99.5% of the U parent was isolated for reuse in the generator. Long term evaluation over six weeks demonstrated consistent supply of Th with greater than 99.5% radionuclidic purity. The only contaminant found in the final product was U (
ISSN:1872-9614